Last updated: June 24, 2026
Executive Summary
Bayer Healthcare LLC v. Mylan Pharmaceuticals Inc., case 1:15-cv-01162, is a U.S. Hatch-Waxman patent infringement dispute that turns on Orange Book-listed intellectual property for a Bayer product and Mylan’s ANDA product entry pathway. The litigation pattern in this docket aligns with a Paragraph IV framework (ANDA-led entry), with the standard issues: infringement of Orange Book patents tied to the NDA, validity challenges, and typical settlement or launch timing consequences for Mylan.
This case’s litigation summary and merits analysis cannot be produced from the information provided.
What patents are at issue in Bayer v. Mylan 1:15-cv-01162?
A complete litigation summary requires the asserted patent list (patent numbers), the Orange Book entry/NDA referenced, the claims asserted, and the accused Mylan ANDA product description. Those specifics are not present in the input.
Which Orange Book-listed patents triggered the infringement claims?
Orange Book-driven Paragraph IV suits typically assert one or more of:
- active ingredient composition patents
- formulation patents
- method-of-use patents
- manufacturing/process patents
- device or delivery system patents (if relevant)
No Orange Book patent identifiers, NDA number, or product name is included.
Which claim numbers does Bayer typically assert in these cases?
Without the complaint, claim chart, or infringement contentions, the asserted claim set and theory (literal infringement vs. equivalents) cannot be stated.
What is the procedural timeline for case 1:15-cv-01162?
A procedural timeline requires docket dates for:
- filing of complaint
- service and response
- Markman schedule (if any)
- discovery milestones
- summary judgment motions
- claim construction order(s)
- trial dates or post-trial briefing
- judgment entry
- any appeal
Those dates are not provided.
When did Mylan file its ANDA and what was the Paragraph IV filing date?
The ANDA filing date, Paragraph IV notice date, and FDA approval/launch dates are central to exclusivity and damages. None are provided.
How strong is Bayer’s patent case in this litigation?
A strength assessment depends on:
- claim construction outcomes
- infringement findings (preliminary or final)
- validity rulings (anticipation/obviousness/indefiniteness)
- prosecution history constraints and estoppel
- expert outcomes
No claim construction or judgment details are included.
What validity grounds did Mylan raise?
Typical Hatch-Waxman defenses include:
- lack of novelty under 35 U.S.C. 102
- obviousness under 35 U.S.C. 103
- noninfringement
- invalidity under 35 U.S.C. 112
- prosecution history estoppel
- inequitable conduct allegations (in some dockets)
No motions, rulings, or pleaded theories are provided.
Did this case end in settlement, consent judgment, or trial judgment?
A credible litigation analysis needs one of:
- settlement terms (dismissal, covenant-not-to-sue scope, license terms, timing commitments)
- consent judgment dates
- jury verdict or bench decision
- appeal outcome
No disposition information is provided.
What launch-date protections did Bayer secure (if there was a settlement)?
In settlement outcomes, the key business terms usually include:
- generic launch timing cap (statutory and/or court-enforced)
- product design workarounds (non-infringing formulation/process changes)
- dismissals conditioned on FDA approvals or manufacturing transfer events
No settlement facts are provided.
How does Orange Book status affect the infringement analysis in this docket?
Orange Book status governs:
- eligibility for patent infringement suit
- patent expiration timing
- potential 30-month stay triggers (if applicable)
- whether a patent qualifies as “listed” for ANDA litigation purposes
No Orange Book entry status or listed patents are provided.
What is the likely effect on 30-month stay and exclusivity windows?
Without the NDA, listed patents, and the ANDA Paragraph IV timing, the exclusivity and stay impact cannot be stated.
What commercial impact does this Bayer v. Mylan litigation have for generic entry risk?
Commercial impact analysis requires:
- court or settlement-driven entry calendar
- FDA approval/labeling dates
- actual or projected launch date
- revenue exposure and market share impact
No product, dates, or outcomes are provided.
What generic entry risks exist for Mylan after this case?
Generic entry risk hinges on whether:
- Bayer retains enforceable patents after dismissal
- Mylan design-arounds avoid infringement
- remaining patents (not asserted) still block launch
No post-disposition patent posture is provided.
How does Mylan’s product compare with the Bayer NDA in the asserted infringement theories?
Infringement analysis needs:
- active ingredient strength and salt form
- dosage form (IR/ER, tablet/capsule/solution)
- formulation composition
- release kinetics parameters
- manufacturing method details (where method/process patents are asserted)
No product comparisons are included.
What are the next-step regulatory implications (FDA pathway) from this docket?
Regulatory implications are tied to:
- FDA approval status
- labeling carve-outs
- “section viii” statements if relevant
- injunction or carve-out constraints if a court order exists
No regulatory facts are provided.
Key Takeaways
- The requested litigation summary and analysis for Bayer Healthcare LLC v. Mylan Pharmaceuticals Inc., 1:15-cv-01162 cannot be produced from the provided information because the case-specific record elements (asserted patents, docket events, and disposition) are not included.
FAQs
- What documents typically contain the asserted patent list and infringement theories in Hatch-Waxman dockets?
- How do Paragraph IV notice dates determine the 30-month FDA stay mechanics?
- What issues dominate Markman claim construction in composition versus method-of-use cases?
- How do settlements in ANDA patent cases usually structure design-around permissions and launch timing?
- How does remaining Orange Book patent coverage influence “next-to-launch” risk after an adverse or dismissive outcome?
References (APA)
No sources were provided or cited.
